Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.83 [0.70, 0.99] | | < 1 | | 0% | 1 study (1/-) | 98.2 % | NA | not evaluable | | crucial | - |
deaths (OS) (extension) | 0.74 [0.61, 0.90] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | important | - |
progression or deaths (PFS) | 1.34 [1.13, 1.59] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | important | - |
objective responses (ORR) | 0.36 [0.25, 0.53] | | > 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
AE (any grade) | 0.31 [0.22, 0.44] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
AE leading to death (grade 5) | 0.84 [0.48, 1.48] | | < 1 | | 0% | 1 study (1/-) | 72.6 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (any grade) | 0.36 [0.23, 0.55] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 0.05 [0.02, 0.09] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 0.09 [0.06, 0.13] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 0.35 [0.09, 1.34] | | < 1 | | 0% | 1 study (1/-) | 93.6 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Adrenal insufficiency TRAE (grade 3-4) | 1.92 [0.06, 57.35] | | < 1 | | 0% | 1 study (1/-) | 35.6 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 0.04 [0.01, 0.16] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 0.16 [0.02, 1.31] | | < 1 | | 0% | 1 study (1/-) | 95.6 % | NA | not evaluable | | non important | - |
Blood and lymphatic system disorders TRAE (grade 3-4) | 0.02 [0.01, 0.07] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Blood creatinine increased TRAE (grade 3-4) | 0.96 [0.02, 48.37] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Colitis TRAE (grade 3-4) | 0.96 [0.13, 6.84] | | < 1 | | 0% | 1 study (1/-) | 51.8 % | NA | not evaluable | | non important | - |
Constipation TRAE (grade 3-4) | 0.96 [0.02, 48.37] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.12 [0.01, 0.94] | | < 1 | | 0% | 1 study (1/-) | 97.8 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.19 [0.02, 1.62] | | < 1 | | 0% | 1 study (1/-) | 93.4 % | NA | not evaluable | | non important | - |
Endocrine disorders TRAE (grade 3-4) | 5.79 [0.29, 116.06] | | < 1 | | 0% | 1 study (1/-) | 12.8 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 0.25 [0.07, 0.92] | | < 1 | | 0% | 1 study (1/-) | 98.1 % | NA | not evaluable | | non important | - |
Gastrointestinal disorders TRAE (grade 3-4) | 0.07 [0.02, 0.23] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
General disorders and administration site conditions TRAE (grade 3-4) | 0.19 [0.08, 0.46] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 3.85 [0.17, 85.65] | | < 1 | | 0% | 1 study (1/-) | 20.0 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 1.92 [0.06, 57.35] | | < 1 | | 0% | 1 study (1/-) | 35.6 % | NA | not evaluable | | non important | - |
Hypophysitis TRAE (grade 3-4) | 1.92 [0.06, 57.35] | | < 1 | | 0% | 1 study (1/-) | 35.6 % | NA | not evaluable | | non important | - |
Infusion-related reactions TRAE (grade 3-4) | 0.31 [0.06, 1.57] | | < 1 | | 0% | 1 study (1/-) | 92.0 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 0.03 [0.00, 0.47] | | < 1 | | 0% | 1 study (1/-) | 99.3 % | NA | not evaluable | | non important | - |
Metabolism and nutrition disorders TRAE (grade 3-4) | 0.26 [0.14, 0.49] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Mucosal inflammation TRAE (grade 3-4) | 0.13 [0.03, 0.58] | | < 1 | | 0% | 1 study (1/-) | 99.6 % | NA | not evaluable | | non important | - |
Myocarditis TRAE (grade 3-4) | 0.96 [0.02, 48.37] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Myositis TRAE (grade 3-4) | 0.48 [0.02, 14.29] | | < 1 | | 0% | 1 study (1/-) | 66.3 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.03 [0.00, 0.47] | | < 1 | | 0% | 1 study (1/-) | 99.3 % | NA | not evaluable | | non important | - |
Nephritis TRAE (grade 3-4) | 3.85 [0.17, 85.65] | | < 1 | | 0% | 1 study (1/-) | 20.0 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.01 [0.00, 0.11] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Pancreatitis TRAE (grade 3-4) | 0.96 [0.02, 48.37] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 2.42 [0.46, 12.55] | | < 1 | | 0% | 1 study (1/-) | 14.8 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 0.11 [0.02, 0.47] | | < 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | non important | - |
Severe skin reaction TRAE (grade 3-4) | 0.29 [0.11, 0.73] | | < 1 | | 0% | 1 study (1/-) | 99.6 % | NA | not evaluable | | non important | - |
Stomatitis TRAE (grade 3-4) | 0.05 [0.00, 0.80] | | < 1 | | 0% | 1 study (1/-) | 98.2 % | NA | not evaluable | | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 0.04 [0.00, 0.27] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
Thyroiditis TRAE (grade 3-4) | 0.96 [0.02, 48.37] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Uveitis TRAE (grade 3-4) | 0.96 [0.02, 48.37] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 0.09 [0.01, 1.73] | | < 1 | | 0% | 1 study (1/-) | 94.2 % | NA | not evaluable | | non important | - |
Weight decreased TRAE (grade 3-4) | 0.96 [0.06, 15.37] | | < 1 | | 0% | 1 study (1/-) | 51.2 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
Abdominal pain AE (grade 3-4) | 0.19 [0.02, 1.62] | | < 1 | | 0% | 1 study (1/-) | 93.4 % | NA | not evaluable | | non important | - |
Acute kidney injury AE (grade 3-4) | 1.93 [0.35, 10.60] | | < 1 | | 0% | 1 study (1/-) | 22.7 % | NA | not evaluable | | non important | - |
Anaemia AE (grade 3-4) | 0.24 [0.13, 0.44] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Asthenia AE (grade 3-4) | 0.31 [0.08, 1.16] | | < 1 | | 0% | 1 study (1/-) | 95.8 % | NA | not evaluable | | non important | - |
Blood and lymphatic system disorders AE (grade 3-4) | 0.10 [0.06, 0.18] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Decreased appetite AE (grade 3-4) | 0.28 [0.08, 1.03] | | < 1 | | 0% | 1 study (1/-) | 97.2 % | NA | not evaluable | | non important | - |
Diarrhoea AE (grade 3-4) | 0.23 [0.05, 1.11] | | < 1 | | 0% | 1 study (1/-) | 96.6 % | NA | not evaluable | | non important | - |
Dyspnoea AE (grade 3-4) | 2.26 [0.58, 8.83] | | < 1 | | 0% | 1 study (1/-) | 12.1 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 0.60 [0.26, 1.42] | | < 1 | | 0% | 1 study (1/-) | 87.7 % | NA | not evaluable | | non important | - |
Febrile neutropenia AE (grade 3-4) | 0.03 [0.00, 0.47] | | < 1 | | 0% | 1 study (1/-) | 99.3 % | NA | not evaluable | | non important | - |
Gastrointestinal disorders AE (grade 3-4) | 0.33 [0.20, 0.56] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
General disorders and administration site conditions AE (grade 3-4) | 0.42 [0.23, 0.75] | | < 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | non important | - |
Hypertension AE (grade 3-4) | 7.74 [0.41, 147.13] | | < 1 | | 0% | 1 study (1/-) | 8.9 % | NA | not evaluable | | non important | - |
Hypothyroidism AE (grade 3-4) | 0.96 [0.02, 48.37] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Increase AST AE (grade 3-4) | 0.38 [0.07, 1.97] | | < 1 | | 0% | 1 study (1/-) | 87.5 % | NA | not evaluable | | non important | - |
Leucopenia AE (grade 3-4) | 0.03 [0.00, 0.47] | | < 1 | | 0% | 1 study (1/-) | 99.3 % | NA | not evaluable | | non important | - |
Metabolism and nutrition disorders AE (grade 3-4) | 0.51 [0.33, 0.77] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
Mucosal inflammation AE (grade 3-4) | 0.25 [0.08, 0.75] | | < 1 | | 0% | 1 study (1/-) | 99.3 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 0.03 [0.00, 0.44] | | < 1 | | 0% | 1 study (1/-) | 99.4 % | NA | not evaluable | | non important | - |
Nervous system disorders AE (grade 3-4) | 0.40 [0.18, 0.85] | | < 1 | | 0% | 1 study (1/-) | 99.1 % | NA | not evaluable | | non important | - |
Neutropenia AE (grade 3-4) | 0.01 [0.00, 0.09] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Pneumonitis AE (grade 3-4) | 0.80 [0.41, 1.56] | | < 1 | | 0% | 1 study (1/-) | 74.1 % | NA | not evaluable | | non important | - |
Rash AE (grade 3-4) | 0.11 [0.02, 0.47] | | < 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | non important | - |
Renal and urinary disorders AE (grade 3-4) | 1.15 [0.35, 3.81] | | < 1 | | 0% | 1 study (1/-) | 40.9 % | NA | not evaluable | | non important | - |
Respiratory, thoracic and mediastinal disorders AE (grade 3-4) | 2.17 [1.12, 4.18] | | < 1 | | 0% | 1 study (1/-) | 1.1 % | NA | not evaluable | | non important | - |
Sepsis AE (grade 3-4) | 2.91 [0.58, 14.53] | | < 1 | | 0% | 1 study (1/-) | 9.7 % | NA | not evaluable | | non important | - |
Skin and subcutaneous tissue disorders AE (grade 3-4) | 1.61 [0.58, 4.50] | | < 1 | | 0% | 1 study (1/-) | 18.0 % | NA | not evaluable | | non important | - |
Stomatitis AE (grade 3-4) | 0.05 [0.00, 0.80] | | < 1 | | 0% | 1 study (1/-) | 98.2 % | NA | not evaluable | | non important | - |
Thrombocytopenia AE (grade 3-4) | 0.03 [0.00, 0.25] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Vascular disorders AE (grade 3-4) | 0.76 [0.35, 1.64] | | < 1 | | 0% | 1 study (1/-) | 76.0 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 0.12 [0.01, 0.94] | | < 1 | | 0% | 1 study (1/-) | 97.8 % | NA | not evaluable | | non important | - |
Weight decreased AE (grade 3-4) | 2.26 [0.58, 8.83] | | < 1 | | 0% | 1 study (1/-) | 12.1 % | NA | not evaluable | | non important | - |